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Current Advances in Biomarkers in Multiple Sclerosis
Thomas Berger
Head of Neuroimmunology and Multiple Sclerosis Clinic & Research Unit, Clinical Department of Neurology, Innsbruck Medical 
University, Innsbruck, Austria
Multiple	sclerosis	(MS),	the	most	important	inflammatory	demyelinating	central	nervous	system	(CNS)	
disease	complex,	 is	characterised	by	heterogenous	 immunopathogenetic	pathways,	various	clinical	
entities	and	disease	courses,	and	finally,	inhomogeneous	and	unpredictable	treatment	effects.	Therefore,	
identification	of	MS-specific	biological	markers	has	continuously	gained	importance	over	the	last	decade.
	 There	is	accumulating	evidence	from	immunological,	pathological,	and	therapeutic	studies	that	B	cells	
(and	antibodies)	are	critically	involved	in	the	pathophysiology	of	MS.	B	cells	(and	antibodies)	seem	to	
play	various	roles	in	the	initiation	and	propagation	of	inflammatory	demyelinating	processes	at	different	
disease	stages	of	MS	and	its	variants.	Recent	therapeutic	trials	indicated	that	monoclonal	antibodies	that	
specifically	target	B	cells	are	effective	in	MS	and	neuromyelitis	optica	(NMO).
	 This	lecture	will	review	the	current	status	and	(potential)	applicability	of	antibodies	in	cerebrospinal	
fluid	(CSF)	and/or	serum	as	biological	markers	for:
(1)	 diagnosis:	value	of	CSF	oligoclonal	IgG	bands	for	MS	(differential)	diagnosis,	value	of	anti-MOG	and	
–AQP4	antibodies	to	distinguish	different	CNS	demyelinating	disorders	(paediatric	and	adult	ADEM,	
CIS	and	NMO)
(2)	 disease	progression:	value	of	antibodies	to	myelin	(eg	MOG,	MBP)	and	non-myelin	antigens	(eg	
neurofascin)
(3)	 repair	and	regeneration:	IgM	antibodies	promoting	remyelination,	antibodies	blocking	inhibitory	
molecules,	eg	NoGo
(4)	 monitoring	disease-modifying	 therapies:	neutralising	antibodies	 (against	 interferon	beta	and	
natalizumab),	risk	assessment	and	treatment	stratification	(anti-JC	virus	antibody	assays)
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Central	nervous	system	inflammatory	demyelinating	disorders	(CNS	IDD)	are	important	diseases	affecting	
patients	of	a	wide	age	range,	and	are	potentially	treatable.	CNS	IDD	can	result	 in	major	neurological	
disabilities	and	even	mortality.	Both	classical	multiple	sclerosis	 (CMS)	and	neuromyelitis	optica	are	
predominantly	characterised	by	relapsing	attacks	of	CNS	inflammatory	demyelination.	The	diagnosis	of	
which	may	be	difficult	especially	in	the	early	phase.	Excitement	has	arisen	from	increasing	numbers	of	
disease-modifying	drugs	(DMDs)	available	for	CMS	in	recent	years.	Beta-interferon	and	glatiramer	acetate	
are	certainly	first-line	DMDs.	Natalizumab,	fingolimod	and	mitoxantrone	are	approved	second-line	DMDs	
for	relapsing	multiple	sclerosis	patients.	Other	DMDs	that	may	be	used	in	refractory	patients	include	
alemtuzumab,	teriflunomide	and	rituximab.	However,	availability,	costs	and	rare	but	serious	side-effects	
are	practical	issues	that	may	limit	the	choice	of	treatment	for	these	patients.	How	about	novel	therapies?
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